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ABSTRACT
Tumor-initiating cells (TICs) play important roles in tumor progression and 
metastasis. Identifying the factors regulating TICs may open new avenues in cancer 
therapy. Here, we show that TIC-enriched prostate cancer cell clones use more 
glucose and secrete more lactate than TIC-low clones. We determined that elevated 
levels of phosphoenolpyruvate carboxykinase isoform 2 (PCK2) are critical for the 
metabolic switch and the maintenance of TICs in prostate cancer. Information from 
prostate cancer patient databases revealed that higher PCK2 levels correlated with 
more aggressive tumors and lower survival rates. PCK2 knockdown resulted in low 
TIC numbers, increased cytosolic acetyl-CoA and cellular protein acetylation. Our 
data suggest PCK2 promotes tumor initiation by lowering acetyl-CoA level through 
reducing the mitochondrial tricarboxylic acid (TCA) cycle. Thus, PCK2 is a potential 
therapeutic target for aggressive prostate tumors.
INTRODUCTION
Emerging data suggest that a subpopulation of 
self-renewing and evolving tumor-initiating cells (TICs), 
popularly known as cancer stem cells (CSCs), may be 
responsible for tumor metastasis, and patient relapse and 
death [1]. Although the biological and clinical relevance 
of TICs/CSCs remains controversial, most solid tumors, 
including prostate cancer tumors, appear to follow the TIC/
CSC model [2]. TICs are resistant to both radiation and 
chemotherapy in conventional treatments [3, 4]. Moreover, 
such treatments enrich TICs in tumors, endowing them 
with more aggressive characteristics. Unfortunately, there 
are no obvious molecular targets for TICs in rational drug 
design, because the molecular pathways underlying TIC 
maintenance are not well understood.
More than 75 years ago, Otto Warburg observed 
that tumor cells, like embryonic cells, preferentially use 
glycolysis to convert glucose carbon to lactate, even under 
aerobic conditions [5]. More recently, reports have shown 
that a single switch to the embryonic isoform of pyruvate 
kinase (PKM2) is necessary for the shift from OXPHOS 
to glycolysis in cancer cells and that this switch promotes 
tumorigenesis [6, 7]. The enhanced glycolysis in cancer cells 
can decrease reactive oxygen species (ROS), and promote 
the pentose phosphate pathway (PPP) and serine/glycine 
synthesis pathway, which are both linked to tumorigenesis 
[8–11].
In addition, yeast and many mammalian cells rely 
on acetyl-CoA for growth [12–15]. Acetyl-CoA is an 
essential building block for synthesis of fatty acids or 
sterols, or for the acetylation of histones on a set of more 
than 1,000 genes critical for cell growth [12]. In well-fed 
mammalian cells, the acetyl-CoA is primarily supplied 
by converting mitochondrial derived citrate into acetyl-
CoA via ATP citrate lyase (ACLY) [16, 17]. In highly 
glycolytic or hypoxic tumors, glucose-derived pyruvate is 
preferentially shunted toward lactate instead of entering 
into the mitochondrial tricarboxylic acid (TCA) cycle 
for production of citrate and acetyl-CoA. It was recently 
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reported that the nucleocytosolic acetyl-CoA synthetase 
enzyme, ACSS2, converts acetate into a key source of 
acetyl-CoA for tumors under such conditions [13, 14].
Many stem cells rely heavily on aerobic glycolysis 
instead of the TCA cycle to produce ATP. In addition, ROS 
production is relatively low due to low OXPHOS; stem 
cells are sensitive to ROS, and either die or differentiate 
under excessive ROS [18, 19]. TICs from different 
types of cancers exhibit higher glycolysis levels than 
non-TICs [20, 21]. Also similar to TICs, the metabolic 
switch from OXPHOS to aerobic glycolysis regulates the 
reprogramming of somatic differentiated cells into induced 
pluripotent stem cells (iPSCs) [18, 19].
The above findings suggest a connection between 
TICs and metabolic reprogramming; however, the 
significance of this connection is still unclear. Here 
we show that elevated levels of phosphoenolpyruvate 
carboxykinase isoform 2 (PCK2) are critical for the 
metabolic switch and maintenance of TICs in prostate 
cancer. TIC-enriched clones expressed a high level of 
PCK2, and PCK2 knockdown resulted in low numbers 
of TICs. In contrast, PKM2 knockdown resulted in 
high TICs. Prostate cancer patient database information 
revealed that higher levels of PCK2 expression were 
associated with more aggressive tumors and lower 
survival rates. PCK2 knockdown resulted in low TIC 
numbers, increased cytosolic acetyl-CoA and cellular 
protein acetylation. Our data suggest PCK2 regulates 
tumor initiation of prostate cancer cells by reducing the 
mitochondrial tricarboxylic acid (TCA) cycle activity and 
thereby production of citrate and acetyl-CoA. Our findings 
suggest that PCK2 is critical for the metabolic switch in 
tumor initiation, and that PCK2 is a potential therapeutic 
target for aggressive prostate tumors.
RESULTS
Isolation of TIC-enriched subclones of prostate 
cancer cell lines
Heterogeneous subclones can be isolated from 
prostate cancer cell lines by culturing single-cell clones 
[22, 23]. Using this method, we isolated several subclones 
from two prostate cancer cell lines, Du145 and PC3/M. 
These clones could be stably subcultured (data not shown). 
Most of the subclones from Du145 could be divided into 
two major types based on their morphology: mesenchymal 
or epithelial-like (Figure 1A). We randomly picked one 
clone of each type for further analysis. Consistent with 
their morphologies, clone D18 (epithelial-like, hereafter 
Du145-EL) showed significantly higher E-cadherin 
expression than the parental cells or the mesenchymal-
like clone B2 (hereafter Du145-ML) (Figure 1B and 
1C). Although a similar morphological difference was 
not observed between the single-cell PC3/M subclones 
(Supplementary Figure 1A), they could also be divided 
into two types based on their E-cadherin expression 
(Supplementary Figure 1B), and we have used PC3/M-EL 
to designate the high E-cadherin expressers and PC3/M-
ML to denote the low E-cadherin clones.
The cell status has been reported to be tightly 
related to TICs. Although many TICs have been found 
to have mesenchymal characteristics and epithelial-
mesenchymal transition (EMT) can produce TICs in some 
cancer types [24, 25], there are also reports about TICs 
enriched in epithelial cell [24]. For example, cells with 
high expression of E-cadherin are reported enriched TICs 
in prostate cancer cells [26, 27]. Indeed, we found that 
the clones that highly expressed E-cadherin (Du145-EL 
and PC3/M-EL) contained many more CD44+/CD24- 
prostate cancer TICs [28, 29] than the E-cadherin-low 
clones (Du145-ML and PC3/M-ML) (Figures 1F and 
Supplementary Figure 1D). To further characterize the 
TICs, we examined the clones’ sphere-forming capacity 
[30]. Du145-EL cells had a strong sphere-forming ability, 
both in the first and second generations (Figures 1A, 1D, 
and 1E), compared to the parental and Du145-ML cells. 
A similar result was found for the clones derived from 
PC3/M: PC3/M-EL cells formed many more spheres than 
PC3/M-ML cells (Supplementary Figure 1A and S1C).
We next examined the tumor-initiating ability of 
these cells using in vivo xenograft assays. Du145-EL 
cells showed a much stronger tumor-initiating ability in 
nude mice than Du145-ML cells. Eight weeks after cell 
injection, 100% of the mice (5 out of 5) in the Du145-EL 
group grew tumors, while only 40% (2 out of 5) in the 
Du145-ML group did (Figure 1G), and the Du145-ML-
derived tumors were significantly smaller (Figure 1H and 
1I) and had a longer latency (Figure 1G) than the Du145-
EL-derived ones.
Thus, the heterogeneous subclones were stable, and 
the EL clones, which were enriched in prostate cancer 
TICs, showed more aggressive characteristics than the 
ML clones.
Enhanced glycolysis in TIC-enriched prostate 
cancer cells
During daily cell culture, we noticed that the Du145-
EL cell culture medium has a more acidic appearance than 
that of the Du145 parental and Du145-ML cell cultures 
(Figure 2A). A change in culture medium color indicates a 
change in its pH. We therefore cultured the same number 
of Du145 parental, Du145-EL, and Du145-ML cells in 
complete medium, and found that the medium from the 
Du145-EL cells had a lower pH than that from the other 
two (Figure 2B). This finding indicated that the cells had 
enhanced glycolysis, or increased glucose consumption 
and lactate production/secretion. Therefore, we measured 
the glucose consumption and lactate production, and 
found they were significantly elevated in the Du145-EL 
cells compared to the Du145 parental and Du145-ML cells 
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(Figure 2C and 2D). The high glucose consumption in the 
Du145-EL cells led us to analyze the cells’ dependence 
on glucose for survival. Most Du145 parental and Du145-
ML cells survived two days of glucose deprivation, most 
Du145-EL cells died under the same condition (Figure 
2E and 2F), showing that the EL cells were intolerant of 
glucose deprivation. We also examined the response of the 
three cell groups to glutamine deprivation and found no 
significant differences between them (Figure 2E and 2F).
Although the PC3/M-EL and PC3/M-ML cells did 
not show significant differences in medium color or pH 
(data not shown), the PC3/M-EL cells showed greater 
glucose consumption and lactate production than the PC3/
M-ML cells (Supplementary Figure 2A and 2B).
Figure 1: Isolation and characterization of a TIC-enriched single-cell clone from Du145 cells. (A) Morphology of the 
Du145 parental cells, Du145-ML clone, and Du145-EL clone (upper), and the first spheres cultured from these cells (bottom). Scale bar, 
100 μm. (B and C) E-cadherin expression level in the Du145 parental cells, Du145-ML clone, and Du145-EL clone detected by qPCR and 
immunoblotting. (D and E) Numbers of first- and second-generation spheres cultured from the Du145 parental cells, Du145-ML clone, 
and Du145-EL clone. (F) Representative flow cytometry results of CD44+/CD24- TICs in the Du145 parental cells, Du145-ML clone, and 
Du145-EL clone. (G) Latency of tumor growth in nude mice. (H) Tumor growth over time. Data are the mean ± SEM from five mice. (I) 
Tumor weight when the xenograft assay was terminated. Data are the mean ± SEM from five mice. *: p < 0.05.
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High PCK2 expression in TIC-enriched prostate 
cancer cells
To understand the molecular basis for the glycolytic 
switch in the TIC-enriched cells, we first examined the 
PKM2 expression in our clones, because enhanced PKM2 
expression is associated with the glycolytic switch in 
cancer cells [6]. However, we did not find elevated PKM2 
expression in the EL clones (Supplementary Figure 
2C), suggesting increased PKM2 expression was not 
responsible for their change in glucose metabolism.
To find genes responsible for this change, we 
compared the gene expression profiles of Du145-
EL and Du145-ML cells using a microarray assay 
(GSE76470). Among the differentially expressed genes, 
the gene encoding PCK2, the mitochondrial form of 
phosphoenolpyruvate carboxykinase, was greatly elevated 
in the EL-clone cells. PCK2 catalyzes the conversion of 
oxaloacetate (OAA) to phosphoenolpyruvate (PEP) and 
is a key enzyme in the feeder reactions of carbon from 
the citric acid cycle to various biosynthetic processes, 
especially the synthesis of serine, glycerol, and nucleotides 
[31]. Using Q-PCR, Western blot, and immunofluoresence 
staining, we confirmed the elevated expression of PCK2 in 
Du145-EL cells (Figures 3A, 3B, and 3C). We also found 
that the PCK2 expression in PC3/M-derived clones was 
similarly elevated in the EL cells (Supplementary Figures 
3A and 3B).
We next examined the PCK2 expression in clinical 
prostate cancer samples. Using published prostate 
cancer microarray datasets, we found a much higher 
PCK2 expression in metastatic prostate cancer samples 
compared to normal tissue or primary cancer tissue in two 
datasets (GDS1439 and GDS2524) (Figure 3D and 3E), 
indicating that PCK2 is highly expressed in aggressive 
prostate cancer. We then analyzed the correlation of 
PCK2 expression with patient survival in two independent 
cohorts (GSE20134 and GSE16560), and found that, in 
both cohorts, patients with high PCK2 expression showed 
a lower survival rate (Figure 3F and 3G).
Figure 2: Enhanced glycolysis in TIC-enriched prostate cancer cells. (A) Culture medium color of the Du145 parental cells, 
Du145-ML clone, and Du145-EL clone. (B) pH of culture medium from the Du145 parental cells, Du145-ML clone, and Du145-EL clone. 
(C) Glucose consumption in the Du145 parental cells, Du145-ML clone, and Du145-EL clone. (D) Lactate production by the Du145 
parental cells, Du145-ML clone, and Du145-EL clone. (E) Cell viability detected by crystal violet staining after two days of glucose 
deprivation (W/O Gluc) or glutamine deprivation (W/O Gln). FM: full medium. (F) Quantification of cell viability after two days of glucose 
deprivation (W/O Gluc) or glutamine deprivation (W/O Gln). FM: full medium. *: p < 0.05; **: p < 0.01.
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PCK2 is critical for the glycolytic switch in TIC-
enriched cells
Considering PCK2’s regulation of OAA and PEP, 
we next examined whether PCK2 was responsible for the 
change in glucose metabolism in TIC-enriched EL cells. 
We used two shRNAs (PCK2i-1 and PCK2i-2) to knock 
down PCK2’s expression in Du145-EL cells. PCK2i-1 
almost completely blocked and PCK2i-2 dramatically 
reduced the PCK2 expression (Figure 4A). Consistent 
with the reported function of PCK2, knocking down PCK2 
significantly reduced cellular PEP level (Supplementary 
Figure 4). We then measured the glucose consumption 
and lactate production in the PCK2-knockdown cells 
(PCK2i-1 or PCK2i-2), and found that both processes 
were decreased compared with control cells that were 
virally transfected with a scrambled sequence (Figure 4B 
and 4C). We also knocked down PCK2 in PC3/M-EL cells 
using the more efficient PCK2i-1 (Supplementary Figure 
3C), and again found reduced glucose consumption and 
lactate production (Supplementary Figures 3D and 3E).
We next used the stable isotope-resolved 
metabolomics (SIRM) approach [32, 33] to analyze 
the metabolic fate of U-13C6-glucose in the Du145-EL 
scramble and PCK2i-1 cells. GS-MS was used to quantify 
13C-labeled metabolites involved in glycolysis and the 
TCA cycle. Consistent with the results we obtained using 
unlabeled experiments, the SIRM results showed a trend 
of lower glucose consumption and lactate production in 
the PCK2-knockdown cells compared to the controls 
(Figures 4E). We also found significant increases in 13C2 
(M2)-citrate, malate, aspartate (markers of the TCA cycle’s 
Figure 3: PCK2 is highly expressed in TIC-enriched prostate cancer cells and is a prognostic indicator for prostate 
cancer patients. (A and B) PCK2 expression in the Du145 parental cells, Du145-ML clone, and Du145-EL clone by qPCR and 
immunoblotting. (C) PCK2 expression (green) in the Du145 parental cells, Du145-ML clone, and Du145-EL clone by immunofluorescence 
staining. Scale bar, 50 μm. (D and E) PCK2 expression in different subtypes of clinical prostate cancer samples. (F and G) Kaplan-Meier 
survival curves for prostate cancer patients grouped according to PCK2 expression. **: p < 0.01.
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Figure 4: PCK2 is responsible for the reprogramming of glucose metabolism in TIC-enriched prostate cancer cells. 
(A) PCK2 knockdown efficiency in Du145-EL cells, as detected by immunoblotting. (B) Glucose consumption in scramble control and 
PCK2-knockdown Du145-EL cells. (C) Lactate production by scramble control and PCK2-knockdown Du145-EL cells. (D) Diagram 
showing the expected 13C (red and green closed circle) labeling patterns of glycolytic and TCA cycle metabolites derived from 13C6-
glucose. The TCA cycle reactions depicted represent PDH (red) or anaplerotic PCB-initiated (green) cycle activity for one cycle turn. PDH: 
pyruvate dehydrogenase; PCB: pyruvate carboxylase; ACLY: ATP-citrate lyase. (E) 13C6-Glucose uptake and 
13C3-lactate production were 
determined by GC-MS analysis of the medium of Du145-EL scramble and PCKi-1 cells grown in 13C6-Glucose (mean ± SEM in triplicate). 
(F to J) 13C-labeled glycolytic and TCA cycle metabolites determined by GC-MS analysis. Data are the mean ± SEM of triplicate samples. 
Doubly and triply 13C labeled citrate are respectively unique markers of PDH and PCB-initiated TCA cycle activity (cf. diagram in D). M0 
to m6 refer to mass isotopologues of TCA cycle metabolites with 0 to 6 13C atoms. (K) Quantification of cell viability after two days of 
glucose deprivation (W/O Gluc). **: p < 0.01.
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first round),13C3-citrate (marker of pyruvate carboxylation) 
and 13C4 (M4)-citrate (marker of the TCA cycle’s second 
round) (Figures 4F, 4G, 4H, and 4I). These results further 
indicated that PCK2 can remodel the glucose metabolism 
in TIC-enriched prostate cancer cells, by enhancing 
glycolysis and reducing the TCA cycle.
We then examined the sensitivity of PCK2-
knockdown cells to two days of glucose deprivation, and 
found that the PCK2 knockdown partially rescued the cell 
death caused by glucose deprivation in both Du145-EL 
cells (Figure 4J) and PC3/M-EL cells (Supplementary 
Figure 3F).
PCK2 and PKM2 differentially regulate TICs in 
prostate cancer cells
To analyze whether PCK2 regulates the TIC 
characteristics of prostate cancer cells, we determined the 
number of TICs in PCK2-knockdown clones using flow 
cytometry. PCK2 knockdown using PCK2i-1 and PCK2i-2 
reduced CD44+/CD24- TICs in the TIC-enriched Du145-
EL cells by over 80% and 50%, respectively (Figure 5A 
and 5B). A similar result was observed in PC3/M-EL cells 
treated with PCK2i-1 (Supplementary Figure 5A and 5B), 
albeit less in extent for the reduction of CD44+/CD24- 
TICs. We also confirmed that the sphere-forming ability 
was significantly inhibited when the PCK2 expression 
was down-regulated in Du145-EL (Figure 5C and 5D) 
and PC3/M-EL (Figures S5C and S5D) cells. Consistent 
with our other findings, when the Du145-EL scramble 
control and PCK2i-1 cells were subcutaneously injected 
into nude mice and the xenograft growth was measured 
weekly, tumors derived from the PCK2-knockdown cells 
were significantly smaller than those derived from the 
scramble control (Figure 5E, 5F and 5G).
Although we did not find a significant difference 
in PKM2 expression between our ML and EL clones, 
because PKM2 is reported to have important roles of 
glycolytic control in cancer cells, we further analyzed 
its regulation of TICs in our system. We knocked down 
the PKM2 expression using a specific shRNA construct 
in both Du145-EL (Figure 5H) and PC3/M-EL cells 
(Supplementary Figure 5E). Consistent with previous 
reports [6], PKM2 knockdown significantly reduced 
glucose consumption and lactate production in both types 
of cells (Figures 5I, 5J, Supplementary Figure 5F, and 
5G), and accumulated PEP (Supplementary Figure 4). 
We then analyzed the TICs by measuring the CD44+/
CD24- subpopulation using flow cytometry. Surprisingly, 
in contrast to the effect of PCK2 knockdown, the down-
regulation of PKM2 significantly increased the CD44+/
CD24- TICs in both clones (Figures 5K, Supplementary 
Figure 5H, and 5I). This finding was inconsistent with 
previous reports showing that PKM2 knockdown can 
block the tumorigenicity of lung cancer and glioma 
cells [6, 34]. Interestingly, we also found that PKM2 
knockdown in Du145-EL cells did not significantly affect 
the cells’ tumorigenicity in nude mice (Figure 5L, 5M, and 
5N). These results suggest that PKM2 is not important for 
the maintenance of TICs in prostate cancer.
PCK2 and PKM2 affect TICs by differentially 
regulating the ROS status
Our SIRM results also revealed an accumulation 
of reduced glutathione (GSH) and total 13C-labeled 
glutathione (GSH/GSSG) in the Du145-EL PCK2i-1 
cells (Figures 6A). The latter suggest enhanced de novo 
glutathione synthesis by PCK knockdown. Glutathione 
is one of the major intracellular defenses against ROS 
[35], altered glutathione level and synthesis in Du145-
EL PCK2i-1 cells indicated a change in ROS status. Two 
major intracellular ROS are hydrogen peroxide (H2O2) 
and superoxide (O2·-), both of which are important for 
regulating the growth, survival, and maintenance of TICs 
[36]. As glutathione primarily reacts with H2O2, we first 
analyzed the H2O2 level with a specific probe, 2', 7’–
dichlorofluorescin diacetate (DCFH-DA). Surprisingly, 
we found only a slight, non-significant decrease in the 
DCFH-DA signal in Du145-EL PCK2i-1 cells (Figure 6B 
and 6C). Since GSH level also increased in Du145-EL 
PCK2i-1, it is possible that PCK suppressed cells have 
less need for GSH for H2O2 removal. As H2O2 is largely 
derived from O2·-, we next examined the intracellular 
O2·- level with a specific superoxide detection probe, 
dihydroethiodium (DHE) and found that the O2·- level was 
significantly higher in the PCK2-knockdown Du145-EL 
cells (Figure 6D and 6E).
An increase in ROS is reported to decrease the TICs 
in cancer cells [37]. To examine whether the increased 
O2·-, rather than H2O2, level in PCK2-knockdown cells 
was responsible for the TIC reduction, we treated the 
cells with two ROS scavengers, N-acetylcysteine (NAC) 
and TempoL. NAC acts as a synthetic precursor to 
glutathione synthesis, to enhance glutathione production 
and reduce the H2O2 level. NAC treatment did not rescue 
the TIC reduction phenotype in PCK2-knockdown cells 
(data not shown), which is consistent with the observed 
accumulation instead of depletion of GSH in these cells. 
However, treating the cells with TempoL, an O2·--specific 
scavenger, significantly increased the proportion of TICs 
(TIC ratio) (Figure 6F). Furthermore, knocking down 
PCK2 in PC3/M-EL cells also induced a significant 
increase in O2·-, and TempoL rescued the TIC ratio in 
these cells (Supplementary Figure 6A, 6B, 6C, 6D, and 
6E). However, increased H2O2 level was evident in PCK2 
suppressed PC3/M-EL cells, unlike PCK2 knockdown 
Du145-EL cells. These results suggest that PCK2 can 
modulate TICs in TIC-enriched prostate cancer cells via 
regulating cellular ROS, particularly the O2·- level.
Because PKM2 knockdown increased the TICs in 
prostate cancer clones, we also examined the ROS level in 
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PKM2-knockdown cells. Unlike the PCK2 knockdown, 
PKM2 knockdown did not affect the O2·- level in Du145-
EL cells (Figure 6D and 6E). However, the H2O2 level 
was dramatically decreased in the PKM2i cells (Figure 
6B and 6C). These results are consistent with a previous 
finding that inhibiting PKM2 activity can enhance the 
PPP and reduce the H2O2 level in lung cancer cells [11]. 
We therefore treated the cells with 6-aminonicotinamide 
(6-AN), a specific inhibitor for 6-phosphogluconate 
dehydrogenase, the first enzyme in the PPP. This 
treatment significantly decreased the proportion of TICs 
in the Du145-EL PKM2-knockdown cells (Figure 6G), 
Figure 5: PCK2 and PKM2 differentially regulate TICs in prostate cancer cells. (A) Representative flow cytometry results 
of CD44+/CD24- TICs in scramble control and PCK2-knockdown Du145-EL cells. (B) Quantification of CD44+/CD24- TICs in scramble 
control and PCK2-knockdown Du145-EL cells. (C) Representative sphere formation results from scramble control and PCK2-knockdown 
Du145-EL cells. Scale bar: 50 μm. (D) Quantification of spheres in scramble control and PCK2-knockdown u145-EL cells. (E) Du145-EL 
scramble and PCK2i-1 cells were injected into nude mice. Tumor volume was monitored weekly. Data are the mean ± SEM from five mice. 
(F) Tumors derived from Du145-EL scramble and PCK2i-1 cells. (G) Tumor weight when the xenograft assay was terminated. Data are the 
mean SEM from five mice. (H) PKM2 knockdown efficiency in Du145-EL cells, as detected by immunoblotting. (I) Glucose consumption 
in scramble control and PKM2-knockdown Du145-EL cells. (J) Lactate production by scramble control and PKM2-knockdown Du145-EL 
cells. (K) Quantification of CD44+/CD24- TICs in scramble control and PKM2-knockdown Du145-EL cells. (L) Du145-EL scramble and 
PKM2i cells were injected into nude mice. Tumor volume was monitored weekly. Data are the mean ± SEM from five mice. (M) Tumors 
derived from Du145-EL scramble and PKM2i cells. (N) Tumor weight when the xenograft assay was terminated. Data are the mean ± SEM 
from five mice. *: p < 0.05; **: p < 0.01.
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Figure 6: PCK2 and PKM2 differentially regulate cellular ROS. (A) Representative HSQC NMR spectra showing the changes 
in 13C abundance (represented by the intensity of 13C-attached 1H peaks) of various assigned metabolites in the Du145-EL scramble (Scr, 
black) and PCK2i-1 (PCKi, red) cells. Also shown is the bar graph of average levels of 13C labeled glutathiones (Gluta, GSH+GSSG) and 
their precursors Gly and Glu; data are represented as mean ± SEM in triplicate. (B) Representative flow cytometry results of the H2O2 
level detected by DCFH-DA staining in the scramble control, and PCK2- and PKM2-knockdown Du145-EL cells. (C) Quantification of 
the H2O2 level in the scramble control, and the PCK2- and PKM2-knockdown Du145-EL cells. MFI: mean fluorescence intensity, 
**: p < 
0.01 (compared to scramble control). (D) Representative flow cytometry results of the O2·- level detected by DHE staining in the scramble 
control, and the PCK2- and PKM- knockdown Du145-EL cells. (E) Quantification of the O2·- level in the scramble control, and the PCK2- 
and PKM2-knockdown Du145-EL cells. MFI: mean fluorescence intensity, *: p < 0.05 (compared to scramble control). (F) Quantification 
of CD44+/CD24- TICs in the scramble control and PCK2-knockdown Du145-EL cells after 1 mM TempoL treatment for 2 days. (G) 
Quantification of CD44+/CD24- TICs in the scramble control and PKM2-knockdown Du145-EL cells after 10 μM 6-AN treatment for 2 
days. (H) HSQC NMR uantification of 13C labeled ribose moiety of adenine nucleotides (AXP) and uracil nucleotides (UXP) in Du145-
EL Scramble and PCK2i-1 cells, data are represented as mean ± SEM in triplicate. The ribosyl unit of AXP and UXP is derived from the 
pentose phosphate pathway (PPP). (I and J) GC-MS quantification of 13C labeled serine and glycine in Du145-EL Scramble and PCk2i-1 
cells, data are represented as mean ± SEM in triplicate. M0 to m3 refer to mass isotopologues of Gly or Ser with 0 to 3 13C atoms. *: p < 
0.05; **: p < 0.01.
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indicating that the increase in TICs in PKM2-knockdown 
cells was partially due to the elimination of intracellular 
ROS through the PPP.
PCK2 regulates TICs by modulating cellular 
acetylation
Two major pathways related to glucose metabolism 
that are important in regulating tumorigenicity are 
the PPP and the serine/glycine synthesis pathway [8, 
9, 11]. However, our SIRM results indicated a slight 
enhancement, rather than attenuation of these two 
pathways in the Du145-EL PCK2i-1 cells (Figures 6H, 6I 
and 6J), indicating that some other mechanism must be 
involved in the PCK2-regulated TIC maintenance.
When analyzing the SIRM results, we noticed a 
small increase of 13C-acetate (product of acetyl CoA) level 
in PCK2i-1 cells (Figure 7B), in addition to increased 
production of 13C-citrate (precursor to cytoplasmic acetyl 
CoA) (Figure 4D). These data point to an enhanced acetyl 
CoA production from citrate in the cytoplasm via the ATP 
citrate lyase (ACLY) action. Consistent with the SIRM 
results, the acetyl-CoA was also significantly increased in 
PCK2i cells (Figure 7C).
Given that acetyl-CoA is a major regulator of 
protein acetylation [12, 17], and protein acetylation 
regulates cancer cell proliferation, survival, and even TIC 
maintenance [38, 39], we examined protein acetylation in 
the PCK2-knockdown cells. Consistent with the increase 
in acetyl-CoA, the Du145-EL PCK2i-1 and PCK2i-2 
cells showed enhanced acetylation in both whole-cell 
lysates and acid-extracted histones (Figure 7D and 7E). 
We also performed immunofluorescence staining, using 
an anti-acetylated lysine antibody, and found enhanced 
cytoplasmic staining of acetylated lysine in the Du145-
EL PCK2i-1 cells (Supplementary Figure 7A). We then 
examined whether this enhanced acetylation was due to 
the increased acetyl-CoA production via ATP citrate lyase 
(ACLY) (Figure 7) in PCK2-knockdown cells. Since 
ACLY’s production of cytoplasmic acetyl-CoA promotes 
protein acetylation [17], we treated the PCK2-knockdown 
cells with an ACLY-specific inhibitor, SB204990. This 
treatment dramatically reduced acetylation in the PCK2-
knockdown cells (Figure 7F).
Since knocking down PCK2 reduced TICs in 
prostate cancer cells, we then asked whether this is 
related to cellular acetylation change. To mimic the 
enhanced acetylation in PCK2-knockdown cells, we 
treated Du145-EL cells with class I and class II histone 
deacetylase (HDAC) inhibitors, SAHA and CI994. SAHA 
and CI994 significantly reduced the TICs in Du145-EL 
cells (Figure 7G and 7B). We then examined whether 
inhibiting acetylation could rescue the TIC reduction in 
PCK2-knockdown cells. SB204990 treatment, which 
dramatically reduced the acetylation in PCK2 knockdown 
cells, also significantly increased the number of TICs in 
these cells (Figure 7H). Together, these results indicate 
that modulation of cellular acetyl CoA level and protein 
acetylation is an important factor in PCK2’s ability to 
maintain TICs in prostate cancer cells.
DISCUSSION
In this study, we grew up subclones from single cells 
of heterogeneous prostate cancer cell lines to obtain TIC-
enriched and TIC-impoverished clones. We analyzed the 
clones’ CD44+/CD24- markers, in vitro sphere formation, 
and tumor formation in xenograft mice. We uncovered 
several important aspects of metabolic reprogramming 
and TIC maintenance in tumorigenesis. First, we found 
that selected TIC-enriched prostate cancer cell clones use 
more glucose and secrete more lactate than their TIC-low 
counterparts.Second,we determined that PCK2 is critical 
for the metabolic switch that generates and maintains 
TICs in prostate cancer. Third, we found that PCK2 and 
PKM2 have opposite roles in regulating TICs and ROS 
production. Fourth, PCK2 knockdown resulted in reduced 
TCA cycle and thereby lower citrate, cytosolic acetyl-
CoA and cellular protein acetylation. Our data suggest 
that by shunting anion OAA as PEP from mitochondria 
to the cytosol PCK2 regulates tumor initiation of prostate 
cancer cells through reducing the TCA cycle, ROS level, 
and production of citrate and acetyl-CoA. Finally, using 
patient databases, we found that higher PCK2 expressions 
are associated with more aggressive tumors and lower 
survival rates in prostate cancer patients. Thus, PCK2 is a 
potential therapeutic target for aggressive prostate tumors.
Compare PCK2 and PKM2 in regulating 
glycolytic reprogramming and TICs
PCK catalyzes the conversion of OAA to PEP 
[31]. It has two isoforms, a cytoplasmic form (PCK1, 
PEPCK-C) and a mitochondrial isoform (PCK2, 
PEPCK-M). PCK2 is a cataplerotic enzyme that can 
directly shunt excess citric acid cycle anion OAA as PEP 
from mitochondria to the cytosol. It was recently reported 
that PCK2 is highly expressed in different cancer cells and 
samples [40, 41]. A recent study also found that PCK2 
can regulate TICs in melanoma cells [42]. However, PCK2 
has been found to be downregulated in TICs in melanoma 
cells and repressed their tumorigenic ability. Opposite 
to those findings in melanoma, we found that PCK2 
was upregulated in more aggressive prostate tumors and 
elevated PCK2 levels enriched TICs.
Recent studies have highlighted the importance of 
the biosynthetic and metabolic pathways of serine and 
glycine in cancer [43]. Serine and glycine are important 
components in the anabolic building blocks for the 
generation of glutathione, nucleotides, phospolipids, and 
other metabolites. PHGDH, the first enzyme of the de 
novo serine synthesis pathway, was found to be amplified 
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in both breast cancer and melanoma [9, 10]. It was 
demonstrated that the pathways of aerobic glycolysis and 
the biosynthesis of serine and glycine are interconnected 
through PKM2 [44, 45]. Pyruvate kinase catalyzes the final 
step in glycolysis by transferring the phosphate from PEP 
to ADP, thereby generating pyruvate and ATP. Cancer cells 
selectively express the less active M2 isoform of pyruvate 
kinase (PKM2) [6]. Serine can bind to and activate PKM2. 
In a condition of serine deprivation, PKM2 activity was 
low, which would result in the accumulation of glycolytic 
Figure 7: PCK2 regulates TIC maintenance by modulating protein acetylation via the citrate-pyruvate shuttle. (A) 
Diagram showing the production of cytosolic acetyl-CoA by ACLY. (B) Quantification of 13C-acetate level in Du145-EL scramble and 
PCK2i-1 cells from HSQC NMR results, data are represented as mean ± SEM in triplicate. (C) Quantification of acetyl-CoA in Du145-EL 
scramble and PCK2-knockdown cells. *: p < 0.05. (D) Cellular acetylation level detected by western blotting in cell lysates of scramble 
control and PCK2-knockdown Du145-EL. Short (left) and longer (right) exposures were used to show the differences. * indicates bands that 
were different between the scramble and PCK2-knockdown cells. (E) Histone acetylation detected by western blotting in acid-extracted 
histone samples from scramble control and PCK2-knockdown Du145-EL cell lysates. (F) Cells were treated with 100 μM SB204990 for 
2 days, then the acetylation level was detected by western blotting in cell lysates. Short (left) and longer (right) exposures were used to 
show the differences. * indicates bands that were different between the scramble and PCK2-knockdown cells. (G) Quantification of CD44+/
CD24- TICs in Du145-EL cells after 2 μM SAHA or 10 μM CI994 treatment for 2 days. (H) Quantification of CD44+/CD24- TICs in 
scramble control and PCK2-knockdown Du145-EL cells after 100 μM SB204990 treatment for 2 days. **: p < 0.01.
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metabolites (such as PEP) and the channeling of them into 
the serine biosynthesis to support cell proliferation [44, 45].
PCK2 directly shunts OAA as PEP from 
mitochondria to the cytosol; therefore both high PCK2 
level and low PKM2 activity should result in accumulation 
of PEP and enhance serine biosynthesis to support cell 
proliferation. We found that the TIC-enriched clones 
express a high level of PCK2, and knocking down PCK2 
significantly reduced CD44+/CD24- TICs in the TIC-
enriched clones Du145-EL and PC3/M-EL; however, 
downregulation of PKM2 significantly increased CD44+/
CD24- TICs in both clones. This is consistent with the 
potential functions of PKM2 and PCK2 in serine synthesis. 
Both the reduction of PKM2 activity and the elevation 
of PCK2 activity are support to channel more carbon 
through the TCA cycle to serine synthesis. However, our 
SIRM results indicated a slight enhancement, rather than 
attenuation of the PPP and the serine/glycine synthesis 
pathway in the Du145-EL PCK2i-1 cells (Figures 6H, 
6I and 6J), indicating that the serine/glycine synthesis 
pathway may be not involved in the PCK2-regulated TIC 
maintenance. We further found that PCK2 knockdown 
resulted in reduced TCA cycle and thereby lower citrate, 
cytosolic acetyl-CoA and cellular protein acetylation. 
Therefore, PCK2 and PKM2 regulate TICs by distinct 
mechanisms. The reduction of PKM2 activity may 
channel more carbon through PEP to serine synthesis for 
increasing TICs, while the elevation of PCK2 activity will 
enrich TICs through reducing the TCA cycle, ROS level, 
and production of citrate and acetyl-CoA.
Consistent with our above observation, it has 
been noted that pluripotent stem cells primarily utilize 
glycolysis for their energy supply, while the differentiated 
cells rely on OXPHOS [18, 19]. Mitochondria, the central 
organelles in most cells, are the main sites for converting 
the final metabolites of carbohydrate, and lipid and amino 
acid to ATP and reactive oxygen species (ROS) through 
the OXPHOS processes by consuming O2 in the TCA 
cycle. However, the mitochondria in human and mouse 
embryonic stem cells are underdeveloped (a small number 
of rounded and non-fused cristae), while mitochondria in 
haematopoietic stem cells (HSCs) are relatively inactive. 
But after bone marrow damage, HSCs undergo rapid 
differentiation, and robust mitochondrial metabolism 
supplies the energy and ROS for this transition. In addition, 
many stem cells, including HSCs and mesenchymal stem 
cells reside in a hypoxic niche in vivo and are quiescent. 
They are generally sensitive to ROS. Excessive ROS 
induces either death or differentiation of stem cells. A 
lower level of ROS is critical for self-renewal of HSCs 
and CSCs in some human and murine breast tumors [37]. 
Together, these data suggest that stem cell metabolism 
can be reprogrammed on the basis of functional demands. 
Self-renewing stem cells rely mainly on aerobic glycolysis 
to maintain their quiescent state to ensure life-long 
tissue renewal capacity, but they have to rapidly switch 
to mitochondrial OXPHOS to meet the robust energy 
demands associated with differentiation [18, 19].
PCK2 maintains TICs by reducing cellular 
acetyl-coA
In both yeast and many mammalian cells, elevated 
levels of acetyl-CoA are associated with cell growth 
[12–15]. The increased acetyl-CoA induces acetylation of 
histones on a set of more than 1,000 genes important for 
ribosome biogenesis, protein translation, and amino acid 
biosynthesis. Our metabolic characterization of PCK2 
knockdown in prostate cancer cells found that knocking 
down PCK2 resulted in acetyl-CoA accumulation, 
increased protein acetylation, and dramatically reduced 
the proportion of TICs. Inhibiting acetylation with an 
ATP citrate lyase (ACLY)-specific inhibitor, SB204990, 
dramatically reduced acetylation and increased the number 
of TICs in the PCK2-knockdown cells (Figure 7). Our 
data suggest that PCK2 promotes tumor initiation through 
lowering acetyl-CoA level by shunting anion OAA as PEP 
from mitochondria to the cytosol and thereby reducing the 
TCA cycle.
There are two possible explanations for the 
appearing inconsistence between the published 
information and our result. First, decreased protein 
acetylation has been reported in some cancer cells, and 
increasing protein acetylation by inhibiting deacetylases 
such as histone deacetylases (HDACs) and NAD+-
dependent sirtuin deacetylases (SIRTs), can inhibit certain 
cancer cells and CSC/TIC growth [46, 47]. Second, TICs 
are resistant to both radiation and chemotherapy (mostly 
targeting growing cells) in conventional treatments [3, 4, 
48], such treatments enrich TICs in tumors and endowing 
them with more aggressive characteristics. TICs are 
relatively quiescent cells; poor conditions for growth 
(such as low acteyl-CoA) may favor their enrichment. Our 
results suggest that targeting tumors by lowering acetyl-
CoA procedures may have the risk to enrich TICs.
PCK2 is a potential therapeutic target for 
aggressive tumors
In the past few years, metabolic reprogramming 
has been rediscovered as a driving force of tumorigenesis 
and used as a new hallmark for cancer [49]. This finding 
has raised the new and exciting expectation that targeting 
metabolic enzymes, such as PKM2, may offer unique 
opportunities in cancer treatment [50]. Most tumor cells 
express relatively less active PKM2 dimers, and the lower 
PKM2 activity promotes the accumulation of upstream 
glycolytic intermediates, which are channeled into serine 
biosynthesis for cell proliferation [44, 45, 50]. Some 
small molecular activators of PKM2 are currently under 
development to suppress tumor growth by increasing 
pyruvate kinase activity [51].
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However, recent findings from PKM2-knockout 
mice suggest that there is a differential requirement for 
pyruvate kinase activity among tumor cell populations 
[50]. Increased pyruvate kinase activity may favor 
the survival of some cancer cells, which complicates 
therapeutic strategies that target PKM2. Our study suggests 
that inhibiting PCK2 may overcome the shortcomings of 
targeting PKM2 and may be therapeutically valuable for 
cancers with elevated PCK2 expression. Elevated PCK2 
has been reported in lung cancer cell lines, non-small cell 
lung cancer samples, and other types of cancer cells [40, 
41]. In prostate cancer patients, high PCK2 is detected 
in more aggressive tumors, and patients with high PCK2 
expression have lower survival rates. These findings 
indicate that PCK2 may play an important role in prostate 
cancer progression. Notably, we found that knocking 
down PCK2 could significantly reduce the proportion of 
TICs in prostate cancer cells, indicating that PCK2 is a 
potential target for therapies against TICs.
MATERIALS AND METHODS
Cell lines and single-cell clones’ isolation
Human prostate cancer cell lines Du145 and PC3/M 
(kindly provided by the DCTD Tumor Repository of 
NCI at Frederick, MD) were cultured in RPMI1640 
supplemented with 10% fetal bovine serum and 100 
units/ml penicillin/streptomycin, at 37°C in a humidified 
atmosphere containing 5% CO2.
Single-cell clones were isolated as previously 
reported [22, 23]. Briefly, cells were suspended in full 
culture medium at ~5 cells/ml, and then dispensed into 96-
well culture plates at 200 μl/well. Each well was carefully 
checked under a phase-contrast microscope after plating. 
Wells containing just one cell were marked and checked 
daily. Holoclones that grew from the marked wells were 
sub-cultured and used for further analysis.
RNA isolation and real-time PCR
Total RNA was extracted from cells using 
the RNeasy® Mini Kit (Qiagen), according to the 
manufacturer's instructions. Using a reverse transcription 
kit (Promega), 1 μg RNA from each sample was processed 
directly to cDNA. Amplification was performed in a 15-μL 
reaction system using SYBR® Advantage® qPCR Premix 
(Clotech). All of the reactions were performed in triplicate 
in a Realplex2 system (Eppendorf). The relative gene 
expression level was quantified as described previously 
[52].
The sequence of each primer was as follows:
Actin:
F: 5’- GATCATTGCTCCTCCTGAGC -3’
R: 5’- ACTCCTGCTTGCTGATCCAC -3’
E-Cadherin:
F: 5’- ACCAGAATAAAGACCAAGTGACCA -3’
R: 5’- AGCAAGAGCAGCAGAATCAGAAT -3’
PCK2:
F: 5’- CATCCGAAAGCTCCCCAAGT -3’
R: 5’- GCAGCCTGGAAACCTCTCAT -3’
Gene microarray
Gene microarray assay was performed in Advanced 
Technology Research Facility at the NCI at Frederick, 
Frederick, MD, USA. Briefly, total RNA was extracted 
from DU145-ML and DU145-EL cells using the RNeasy® 
Mini Kit (Qiagen), according to the manufacturer's 
instructions. Qualified RNA was hybridized on Affymetrix 
human gene ST 1.0 microarrays. After scanning and 
normalization, the microarray data were analyzed by 
Partek Genomics Suite 6.6.
Immunoblotting and immunofluoresence 
staining
Cells were washed twice with PBS and lysed in 
RIPA buffer. Protein concentrations were quantified 
using the Bradford reagent (Bio-Rad) according to the 
manufacturer's instructions. Samples with equal amounts 
of protein were separated by 4%–15% SDS-PAGE, 
then transferred to an Immobilon transfer membrane 
(Millipore) and immunoblotted with specific antibodies 
against E-cadherin, PCK2, PKM2, and Acetylated-Lysine 
(Ac-K2-100, #9814) from Cell Signaling, and GAPDH 
from Thermo Scientific. All of the immunoblots were 
visualized by enhanced chemiluminescene (Bio-Rad).
Immunofluoresence staining was performed to 
detect PCK2 expression and protein acetylation. Cells 
were plated in a 24-well multiwell glass-bottomed culture 
plate (MatTek), fixed in 4% formaldehyde in PBS for 15 
min at room temperature, and then washed three times 
with PBS. After being blocked with PBS containing 5% 
goat serum and 0.3% Triton X-100 at room temperature 
for 1 h, the cells were incubated overnight with anti-
PCK2 primary antibody (1:100, Cell Signaling) or anti- 
acetylated-Lysine (1:200, Cell Signaling #9441) at 4°C. 
The secondary antibody, Alexa Fluor 488-conjugated 
donkey anti-rabbit IgG (Molecular Probes) was used at 
a 1:1000 dilution. Fluorescence was monitored by an 
inverted confocal laser microscope (Carl Zeiss).
Flow cytometry
Cell-surface markers and cellular ROS were 
analyzed by flow cytometry. To detect cell-surface 
markers, cells were dissociated by 0.05% trypsin-
EDTA and centrifuged. The cells were resuspended in 
PBS containing 2% FBS and fluorescence-conjugated 
antibodies, FITC-CD44 (clone G44-26, BD Biosciences) 
and PE-CD24 or APC-CD24 (clone ML5, Biolegend), and 
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incubated on ice for 30 min. After three washes in PBS 
containing 2% FBS, the cells were resuspended in PBS 
containing 2% FBS and analyzed by FACSCalibur (BD 
Biosciences).
To detect cellular ROS, cells were incubated with 
5 ng/ml DCFH-DA (Santa Cruz) or 10 μM DHE (Life 
Technologies) at 37°C for 30 min. They were then 
dissociated by 0.05% trypsin-EDTA and centrifuged. After 
being washed with PBS containing 2% FBS, the cells were 
resuspended in PBS containing 2% FBS and analyzed by 
FACSCalibur (BD Biosciences).
Sphere formation assay
Cells were cultured in a Corning® Costar® Ultra-
Low attachment 24-well plate (Sigma-Aldrich) in sphere 
culture medium DMEM/F12 (1:1) with B27 (Invitrogen) 
and 20 ng/ml EGF (Invitrogen). For Du145 and its derived 
clones, new medium was added every three days. For 
PC3/M-derived clones, the cells were cultured in the 
sphere culture medium for three days, then sphere culture 
medium with 0.5% FBS was added every three days. The 
spheres were counted after 10 days in culture.
Glucose, lactate, PEP and acetyl-coA detection
The concentration of glucose and lactate in the cell 
culture medium and of PEP and acetyl-CoA in cell lysate 
was detected by a glucose assay kit (Eton Bioscience), 
L-lactate assay kit I (Eton Bioscience), PEP Fluorometric 
Assay Kit (Cayman) and the PicoProbe™ Acetyl-CoA 
Fluorometric Assay Kit (Biovision), respectively. The 
assays were performed as instructed by the manufacturer.
shRNA knockdown of PCK2 and PKM2
The PCK2 shRNA constructs (TRCN0000052666 
and TRCN0000052667) were purchased from MISSION 
shRNA at Sigma-Aldrich. A PKM2 shRNA construct 
(plasmid: 42516) and a scramble control construct 
(plasmid: 1864) were purchased from Addgene. The 
shRNA constructs were co-transfected with three 
lentiviral packaging plasmids into 293T cells. The culture 
medium containing lentivirus was harvested two days 
after transfection. Cells were infected with the harvested 
medium (filtered with 0.45 μm filter) and selected with 1 
μg/ml puromycin (Invivogen).
In vivo tumorigenicity assay
Cancer cells were injected into the flank of six-
week-old male nude mice. The cell amounts were as 
follows: 1 million/site for Du145 parental, Du145-ML, 
and Du145-EL cells; 0.4 million/site for scramble control 
and PCK2-knockdown (PCK2i-1) Du145-EL cells; 1 
million/site for scramble control and PKM2-knockdown 
Du145-EL cells. Tumors were measured weekly with a 
caliper and calculated using the formula: volume = 0.5 × 
length × width2. The results are presented as the mean ± 
SE. All animals used in this research project were cared 
for and treated humanely according to the following 
policies: the U.S. Public Health Service Policy on Humane 
Care and Use of Laboratory Animals (2000); the Guide 
for the Care and Use of Laboratory Animals (1996); and 
the U.S. Government Principles for Utilization and Care 
of Vertebrate Animals Used in Testing, Research, and 
Training (1985). All NCI at Frederick animal facilities and 
the animal program are accredited by the Association for 
Assessment and Accreditation of Laboratory Animal Care 
International.
Stable isotope-resolved metabolomic (SIRM) 
experiment with 13C6-glucose tracer
Du145-EL scramble (Scr) and PCK2i-1 cells were 
cultured in the RPMI1640 medium with 0.2 % unlabeled 
or 13C6-glucose for 24 hrs, as described previously [53]. 
Acetonitrile/water/chloroform (2/1.5/1, v/v) partitioning 
method was used to extract polar metabolites from cell 
and media. The extracts were subjected to NMR and GC-
MS analysis as previously described [32].
Statistical analysis
Statistical analysis was performed using SPSS 
13.0 for Windows. The data were presented as mean 
values ± standard deviation, except those from the in vivo 
tumorigenicity assay. Statistically significant differences 
were determined by Student’s t-test and one-way ANOVA, 
where appropriate, and defined as P < 0.05.
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